243 related articles for article (PubMed ID: 36760083)
1. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
[TBL] [Abstract][Full Text] [Related]
3. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
4. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
[TBL] [Abstract][Full Text] [Related]
8. Ensitrelvir as a potential treatment for COVID-19.
McCarthy MW
Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 3CL
Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
[TBL] [Abstract][Full Text] [Related]
11. Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
Bouzidi HS; Driouich JS; Klitting R; Bernadin O; Piorkowski G; Amaral R; Fraisse L; Mowbray CE; Scandale I; Escudié F; Chatelain E; de Lamballerie X; Nougairède A; Touret F
Antiviral Res; 2024 Feb; 222():105814. PubMed ID: 38272321
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
[TBL] [Abstract][Full Text] [Related]
14. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
[TBL] [Abstract][Full Text] [Related]
15. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
Medicine (Baltimore); 2023 Feb; 102(8):e33024. PubMed ID: 36827007
[TBL] [Abstract][Full Text] [Related]
16. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Sasaki M; Tabata K; Kishimoto M; Itakura Y; Kobayashi H; Ariizumi T; Uemura K; Toba S; Kusakabe S; Maruyama Y; Iida S; Nakajima N; Suzuki T; Yoshida S; Nobori H; Sanaki T; Kato T; Shishido T; Hall WW; Orba Y; Sato A; Sawa H
Sci Transl Med; 2023 Jan; 15(679):eabq4064. PubMed ID: 36327352
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
[TBL] [Abstract][Full Text] [Related]
18. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
Reina J; Iglesias C
Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
[TBL] [Abstract][Full Text] [Related]
19. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
[TBL] [Abstract][Full Text] [Related]
20. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites.
Iketani S; Hong SJ; Sheng J; Bahari F; Culbertson B; Atanaki FF; Aditham AK; Kratz AF; Luck MI; Tian R; Goff SP; Montazeri H; Sabo Y; Ho DD; Chavez A
Cell Host Microbe; 2022 Oct; 30(10):1354-1362.e6. PubMed ID: 36029764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
